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Abstract
Short-actingb agonists (e.g., albuterol) are themost commonlyusedmedications for
asthma, a disease that affects over 300 million people in the world. Metabolomic
profiling of asthmatics taking b agonists presents a new and promising resource for
identifying themolecular determinants of asthmacontrol. Theobjective is to identify
novel genetic and biochemical predictors of asthma control using an integrative
‘‘omics’’ approach. We generated lipidomic data by liquid chromatography tandem
mass spectrometry (LC-MS), usingplasmasamples from20 individualswithasthma.
Theoutcomeof interestwas abinary indicatorof asthmacontroldefinedby theuseof
albuterol inhalers in the preceding week. We integrated metabolomic data with
genome-wide genotype, gene expression, and methylation data of this cohort to
identify genomic and molecular indicators of asthma control. A Conditional
Gaussian Bayesian Network (CGBN) was generated using the strongest predictors
from each of these analyses. Integrative and metabolic pathway over-representation
analyses (ORA) identified enrichment of known biological pathways within the
strongest molecular determinants. Of the 64 metabolites measured, 32 had known
identities. The CGBNmodel based on four SNPs (rs9522789, rs7147228, rs2701423,
rs759582) and two metabolites—monoHETE_0863 and sphingosine-1-phosphate
(S1P) could predict asthma control with anAUCof 95%. IntegrativeORA identified
17 significantly enriched pathways related to cellular immune response, interferon
signaling, and cytokine-related signaling, for which arachidonic acid, PGE2 and S1P,
in addition to six genes (CHN1, PRKCE,GNA12,OASL,OAS1, and IFIT3) appeared
to drive the pathway results. Of these predictors, S1P, GNA12, and PRKCE were
enriched in the results from integrative andmetabolic ORAs. Through an integrative
analysis of metabolomic, genomic, and methylation data from a small cohort of
asthmatics, we implicate altered metabolic pathways, related to sphingolipid
metabolism, in asthma control. These results provide insight into the pathophysiol-
ogy of asthma control.
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Introduction
Asthma affects over 300 million individuals in the world [1],
and the primary reliever medications used in asthma are
short-acting b2 agonists (SABA, e.g., albuterol) which relax
bronchial smooth muscle by activating b2-adrenergic
receptors. Use of SABA is a recognized marker for
uncontrolled asthma [2], which leads to asthma exacer-
bations, the most common health-related cause of lost
school and work days and contributes to the more than $50
billion spent annually on asthma [3, 4]. Asthma is a complex
disease with both environmental and genetic components [5,
6]. Although a number of genetic determinants have been
identified [7], much remains to be understood about how
these variants impact the maintenance and control of the
disease, and how these can lead to exacerbations. Metab-
olomics, the systematic analysis of small molecules, has been
successfully used to identify new disease biomarkers [8–10].
Metabolomics provides an integrated profile of biological
status reflecting the net results of genetic and environmental
interactions [11, 12], thereby making this a promising new
strategy to examine in the context of asthma control, an
approach that has already been advocated in the litera-
ture [13]. In contrast to transcriptional, translational, and
post-translational changes, metabolites have the distinct
advantage of being more proximal markers of disease
processes. Metabolic profiling can also capture the history of
past exposures such as hypermethylation and response to
hypoxia, making this approach particularly relevant to
asthma [14]. Therefore, metabolomic analysis offers a novel
approach for understanding asthma control.
To date, few metabolomics studies have been performed
with asthma [14–21]. Furthermore, none of these studies
utilized other forms of genomic data to inform their
findings. The objective of this study was to identify novel
predictors of asthma control using an integrative ‘‘omics’’
approach that integrates genotype, expression, metabolo-
mics, and methylation profiling data.
Materials and Methods
Study population
The Asthma BioRepository for Integrative Genomic Explo-
ration (Asthma BRIDGE) is an open-access collection of
cDNA and DNA from primary asthma-relevant cell types
and immortalized cell lines from more than 1,450 well-
characterized subjects participating in ongoing genetic
studies of asthma, and an accompanying database of
phenotype, genome-wide SNP genotype, gene expression,
and methylation data. For this analysis, we obtained samples
for 20 individuals from the Childhood Asthma Research and
Education (CARE) Network cohort, a subset of Asthma
BRIDGE [22]. The CARE Network enrolled children aged
1–18 years with a confirmed diagnosis of asthma or wheezing
illness [23]. Details relating to the study protocols were
previously published [22]. We stratified our cohort into
patients with uncontrolled and controlled asthma based on
self-reported use of SABA inhalers in the week preceding
blood draw for Asthma BRIDGE genomic assays, as an
indicator of asthma control.
Data
Metabolomic profiling
We used liquid chromatography tandem mass spectrome-
try (LC-MS) to measure lipid metabolites. Quadrupole
orbitrap mass spectrometers (two Q Exactive and one
Exactive Plus MS, Thermo Scientific) enabled the
measurement of high-resolution metabolites of both
known and unknown identities in the same experiment.
Targeted datasets contained lists of metabolites of known
identity and the integrated LC-MS peak areas measured in
each sample. Targeted datasets contained a large number
of de-isotoped LC-MS peaks per sample that were indexed
by mass to charge ratio and retention time. A subset of
these signals was readily identified by comparison to
reference standards and reference samples. Lipids were
extracted from plasma (10mL) using 19 volumes of 100%
isopropanol. Extracts were separated using reversed phase
chromatography and full scan MS data were acquired in
the positive ion mode. A total of 68 metabolites were
generated, of which two had no variation, and another two
had missing values for more than half the subjects. These
metabolites were removed before further analysis, leaving
64 metabolites successfully assayed. Principal component
analysis (PCA) identified four subjects as possible outliers;
these were included in subsequent analyses when
appropriate.
Genome-wide gene expression profiling
Existing data were obtained through Asthma BRIDGE.
Stimulated CD4þ T-cell lymphocyte RNA samples from
CARE were previously processed as part of a group of 2,317
samples of diverse tissues from within Asthma BRIDGE as
follows. The samples were assayed for 47,036 different
transcripts using Illumina Human HT-12 v4 arrays, as per
manufacturer’s protocol (Illumina, Inc., San Diego, CA).
After removing 27 outlier probes, the expression values of
the remaining 47,009 probes were log2-transformed and
quantile-normalized. Among the 2,068 non-duplicate
Asthma BRIDGE samples with good signal-to-noise ratios
(p95/p05>6), 16 were CARE samples that had also been
successfully assayed for each of 64 metabolites. PCA of gene
expression identified two CARE outliers, which were
removed from related downstream analyses.
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We tested the association between each metabolite with
each of the 47,009 mRNA probes, adjusted for age and
gender, using the limma Bioconductor package for the R
programming language [24]. Association findings that were
due to high leverage points were removed. Analyses were
adjusted for multiple testing using the False Discovery
rate (FDR) [25].
Genome-wide methylation profiling
Existing data were obtained through Asthma BRIDGE.
Genome-wide DNA methylation data was obtained on
CD4þ T-cell samples using the Illumina HM450 methyla-
tion platform as part of the Asthma BRIDGE cohort of 360
CD4þ samples and 690 whole blood samples. Each array
assesses methylation at 485,577 CpG sites, including 473,921
autosomal and 11,656 CpG sites from chromosomes X or Y.
Quality control (QC) steps were performed by the Channing
Division of Network Medicine, and applied norm-exponen-
tial background correction on raw data reads for each sample
plate. Then the norm-exponential corrected plates were
combined and four samples that were outliers were removed.
Finally dye-bias correction and further quantile normaliza-
tion on the above data set was applied.
Thirteen CARE subjects had successful methylation
assays. We then removed 43 methylation probes that had
missing values for more than half of the remaining subjects.
We further excluded 3,091 cross hybridizing probes and 65
SNP probes, resulting in a total of 482,378 methylation
marks (135,464 type I CpG sites and 346,914 type II CpG
sites). Some subjects had duplicate arrays of CD4þ
methylation data; in these cases we analyzed only the array
demonstrating the largest inter-quartile range (IRQ). We
performed PCA to identify possible batch effects. The first
two principal components (PCs) were clearly related to
gender and plate effects, which were subsequently adjusted
for in the analyses. For each of the 64 metabolites, we tested
the association of each CpG site, adjusted for age and the first
two methylation principal components, with each metabo-
lite. Type I and type II probes were analyzed separately using
statistical routines from the limma package available
through Bioconductor [24]. For each metabolite and for
each type of CpG sites, p-values for metabolite–CpG
association will be adjusted for multiple testing so that false
discovery rate (FDR) will be controlled (<0.05).
Genome-wide genotyping
We obtained data on genome-wide SNPmeasurements from
the Asthma BRIDGE. Genotyping was originally performed
through the SNP Health Association Resource (SHARe)
Asthma Resource Project (SHARP), by Affymetrix Inc.
(Santa Clara, CA), according to manufacturer’s protocol
using the Affymetrix Genome-Wide Human SNP Array 6.0.
This genotype data are archived on the database of
Genotypes and Phenotypes (dbGaP) (http://www.ncbi.
nlm.nih.gov/gap/) for all CARE participants. This resulted
in 400,741 high-quality SNPs, which were included in our
association tests.
We performed linear association tests with all 64
metabolites and all 400,741 SNPs under an additive model
using PLINK [26] (v1.07) on the full cohort of 20 CARE
subjects. Missing metabolite values were imputed with the
mean value for that metabolite, to bias toward the null
hypothesis while preserving as much of the cohort as
possible. Association tests were modeled as linear regressions
with metabolite concentration using age and sex
as covariates.
Table S8 shows if a subject had genotype data, metabolite
data, expression data, or methylation data. There are nine
samples having all four types of data.
Network methods
Overview
Figure 1 summarizes our overall integrative genomic
approach. We first performed genome-wide analyses using
SNPs, mRNA gene expression probes, and CpGmethylation
sites for all 64 metabolites as phenotypic outcomes. The top
association results from each of these analyses, all
metabolites, and the asthma control phenotype were used
as input into the integrative genomics analyses. Two such
analyses were performed. The first analysis was a statistically
driven conditional Gaussian Bayesian Network (CGBN)
analysis, where variants that contribute to the predictive
accuracy of the asthma control phenotype were identified.
The second analysis was a knowledgebase-driven overrepre-
sentation analysis (ORA) that identified key pathways that
are enriched in individuals with poorer asthma control.
Bayesian networks
The expression, SNP, and methylation probes were each
ranked according to most significant p-value. The top 20
associations to one or more metabolites were selected in
combination with the 64metabolites to be used in a Bayesian
network analysis. SNPs in tight linkage disequilibrium
(D0 ¼ 1) were filtered, and missing CpG methylation values
were imputed with the mean value, to bias toward no
association. Continuous variables were then normalized.
This resulted in a dataset of 64 metabolites, 19 SNPs, 19 CpG
methylation sites, and 20 mRNA gene expression probes, as
well as age and sex, combined with the asthma control
phenotype for the full 20 CARE patients.
A conditional Gaussian Bayesian network (CGBN) was
learned from this data using the CGBayesNets package in
MATLAB version R2013b (MATLAB, The Mathworks Inc.,
CGBayesNets [27], www.cgbayesnets.com). CGBN is a
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machine learning technique that makes a network model of
the data using the statistical (Bayesian conditional indepen-
dence) relationships present in the dataset [28]. Similar
CGBN methodologies have been effective in generating
predictive models of intensive care-unit mortality from
metabolomic profiling [29]. The CGBN was learned using a
low uniform Dirichlet prior (and g prior for continuous
nodes) to keep the number of edges low; a technique that has
been shown to be effective in prediction in genomic
contexts [30] and induces a sparse network with a high
complexity penalty [31]. We then performed 250 bootstrap
realizations of the dataset; a technique that helps correct for
small data samples by reducing the effect of outliers within
the population. For each bootstrap realization, we learned an
exhaustive network using a greedy search thatmaximized the
posterior likelihood of the data given the network. This
algorithm starts with an empty network and at each step adds
the edge that maximized the posterior likelihood, out of all
possible edges. Further details can be found in McGeachie,
Chang, and Weiss [27]. To obtain a final consensus network
from the bootstrap networks, we started with an empty
network and added edges sequentially starting with the most
commonly occurring in bootstrap samples, and proceeding
to less commonly occurring edges, and in each case
measured the area under the curve (AUC) of the network
so obtained by using fivefold cross validation (CV) on the 20
samples. The network that maximized the CV AUC
(AUC¼ 95.31%) was obtained using an edge threshold of
10.4%, a network that included edges occurring in at least
10.4% of all bootstrap sample networks.
Metabolite pathway analysis
For pathway over-representation analysis (ORA) of case-
control metabolite data manner, Metabolomics Pathway
Analysis (MetPA) (http://metpa.metabolomics.ca/MetPA/
faces/Home.jsp) [32] was used. MetPA evaluated a list of the
64 metabolites and their log-normalized concentration data
in the 20 samples, by comparing individuals that used rescue
albuterol at least once (cases) to those who did not use
albuterol (controls). Metabolites were evaluated for pathway
enrichment using the ‘‘Homo sapiens’’ library with the
default parameters (‘‘Global Test’’ and ‘‘Relative Between-
ness Centrality’’) specified as the algorithms for pathway
enrichment and topological analysis, respectively. The
resulting metabolic networks were represented as directed
graphs, and centrality measures of a metabolite within a
given network were then applied to estimate the relative
importance of that metabolite in the network. For
topographical analysis, the ‘‘pathway impact’’ score for a
given metabolite was then calculated as the sum of the
Figure 1. Overviewof study design. Directed relationships between top genomic predictors, topmetabolites, and asthma control phenotypeswere used
as input for an integrative genomics pipeline. The two outputs of this pipeline were relationships of pathways and Bayesian predictors, respectively, with
asthma control. IXG, integrative genomics; CGBN, conditional Gaussian Bayesian networks; ORA, over-representation analysis.
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importance measures of that metabolite normalized by the
sum of importance measures for all nodes within each
pathway. Univariate tests were then performed to evaluate
the distribution of individual metabolite concentrations in
individuals with good and poor asthma control.
Integrative pathway analysis
To integrate metabolomic and gene expression data
simultaneously, ORA and Wilcoxon pathway enrichment
analysis (WEA) were performed using Integrated Molec-
ular Pathway Level Analysis (IMPaLA) (http://impala.
molgen.mpg.de/) [33]. We selected the top 20 gene
probes based on their association p-values with any of the
given metabolites. A list of the 64 metabolite IDs, gene
IDs, and fold differences in metabolite concentrations
and gene expression values for cases and controls were
uploaded into the IMPaLA webserver, specifying the
metabolites and genes present across all pathways in the
database as the background list for comparison. For ORA,
the hypergeometric distribution with BH-adjustment of
p-values was applied to determine the significance of
pathways that overlap with the metabolite and gene query
lists. For WEA, the Wilcoxon test was used. Joint p-values
for genes and metabolites were calculated for each
pathway using Fisher’s method. For both approaches,
only pathways with one or more overlapping gene and
metabolite pair were evaluated. Pathways with unadjusted
p-values <0.05 were considered significant. p-Values were
corrected for multiple testing using the FDR (threshold of
0.05).
Genes were also mapped to pathways independently of
phenotype information, using WebGestalt (http://bio-
info.vanderbilt.edu/webgestalt/) webserver tools [34],
specifying the human genome as a reference list, and
using the hypergeometric distribution with BH-adjust-
ment to evaluate the significance of pathways. To
investigate pharmacogenetic pathways, pathway analysis
was performed using WebGestalt to query the drug-
associated genes annotated in the database,
PharmGKB [35]. For all results, pathways with unad-
justed p-values <0.05 were considered significant.
Graphs of gene networks were generated using
GeneMania [36].
In silico validation using the connectivity map
The Connectivity Map (www.broad.mit.edu/cmap)
(CMAP) is a publicly available, searchable database of
gene expression profiles collected from treatment of
human cell lines with small molecules [37]. A gene-
expression signature for ‘‘salbutamol’’ (a.k.a. albuterol)
was generated using data from two independent experi-
ments conducted in PC3 cells, specifying probe expression
threshold values of 0.67 to 0.67 (corresponding to
twofold changes in gene expression) for up- and down-
regulated probe sets. This signature was used to query
CMAP for compounds with correlated effects on gene
expression, emphasizing the lipid metabolites evaluated in
this study. A gene signature for ‘‘dinoprostone’’ (a.k.a.
PGE2) was similarly generated, and genes within the
signature were then evaluated for metabolite pathway
enrichment using WebGestalt.
Results
Description of the study cohort
Descriptive and clinical characteristics of the cohort are
shown in Table 1, stratified by SABA use. A cutoff of zero
versus one or more uses of SABA to identify cases and
controls was a natural point of dichotomy for a pharmaco-
logical outcome. Subjects in the two categories did not differ
significantly, apart from SABA use.
Table 1. Demographic and descriptive characteristics of study subjects.
Frequency of albuterol use in last 7 days
None (n¼ 12) 1 (n¼ 8) p-value
Age (mean, range) 13.3 14.9 0.77
Age at asthma symptom onset (mean, range) 2.5 3.8 0.79
Gender (% female) 25 50 0.25
Race (% self-reported European ancestry) 100 100 1.00
Allergic rhinitis (%) 50 88 0.09
Eczema (%) 42 63 0.36
Food allergy (%) 33 25 0.69
Use of inhaled corticosteroids in last 7 days (%) 42 50 0.71
Baseline characteristics of study subjects are shown, stratiﬁed by exacerbation phenotype. p-Values are computed using x2 test of Fisher exact test, as
appropriate.
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Metabolite profiling
The characteristics of all 64 lipidmetabolites are presented in
Table S1. The distributions of metabolite concentrations are
shown in Figure 2. While metabolite concentrations varied
greatly across the cohort, themetabolite concentrations were
not significantly different between subjects, with or without
SABA use, after adjusting for multiple testing, although
decreases in monoHETE_0863 were nominally associated
with well-controlled asthma (p¼ 0.015). To further investi-
gate the correlation structure between various metabolites
and the case/control status of our cohort, we conducted
unsupervised two-dimensional hierarchical clustering of the
metabolite concentrations by CARE participant (Figure S1).
While none of the subjects could be differentiated into
groups by SABA use based on correlated metabolite clusters,
some of the individual metabolites were correlated with each
other. The correlated metabolites included tauroursodeox-
ycholic acid (a.k.a. ursodeoxycholyltaurine) and taurocholic
acid (r2¼0.95), which are both bile acids. In addition, there
was a cluster of four correlated metabolites: stearic acid,
docosapentaenoic acid, adrenic acid (a.k.a. all-cis-
7,10,13,16-docosatetraenoic acid), and palmitic acid (all
r2> 0.9); stearic acid and palmitic acid are common
saturated fatty acids produced from triglyceride and
carbohydrate metabolism, while docosapentaenoic acid
and adrenic acid are eicosanoids derived from a-linoleic
acid and arachidonic acid, respectively. Docosahexaenoic
acid and eicosatrienoic acid (r2¼ 0.93), both eicosanoids,
were also tightly correlated. No other metabolite correlations
were |r2|> 0.9. Finally, a group of five bile acids (taur-
ochenodeoxycholic acid, tauroursodeoxycholic acid, taur-
ocholic acid, glycocholic acid, and glycoursodeoxycholic
acid) were anti-correlated with the majority of other
metabolites (Figure S1; five right-most columns). These
data show that while specific metabolite concentrations
could be correlated with one another across samples, the case
and control groups could not be differentiated from each
other based solely on the correlation of metabolite
concentrations.
Figure 2. Concentrations (log2) across 64metabolites for 16 CARE subjects. The distribution of eachmetabolite across the study cohort is presented as a
boxplot.
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Pathway analysis of metabolites
None of the pathways were significantly associated with
asthma control (Table 2). As a result, the pathway impact
scores were used instead of p-values to rank pathways in
order of priority. Five pathways had impact scores above 0.
The ‘‘Arachidonic Acid Metabolism’’ and ‘‘Linoleic Acid
Metabolism’’ pathways possessed the greatest number of
overlapping metabolites and the highest pathway impact
scores (Fig. 3A). Within the ‘‘Linoleic Acid Metabolism’’
node, two overlapping query metabolites, linoleic acid
(KEGG: C01595) and g-linoleic acid (KEGG: C06426),
showed higher concentrations in the cases, although these
differences were not significant (Fig. 3B). Similarly, for the
arachidonic acid pathway, six overlapping metabolites
(arachidonic acid (KEGG: C00219), 5-HETE (KEGG:
C04805), PGE2 (KEGG: C00584), 12(S)-HPETE (KEGG:
C05955), 15(S)-HETE (KEGG: C04742), and LTB4
(KEGG: C02165)) demonstrated differential concentrations
in cases and controls, but these differences were not
significant (Fig. 3C).
Association of metabolites with “omics” data
SNP–metabolite associations
Although our low sample size lead to underpowered
interrogation of SNP–metabolite associations, four had
FDR< 0.05. Further, of 64 400,741 SNP-metabolite
association tests, 31 associations were present with an
FDR< 0.20 (shown in Table S2). Since the low power may
miss some important associations, we chose a more lenient
FDR 0.20 cutoff, which allowed us to prioritize a selection of
top associations for further analysis. Of these 31 associations,
two are in or near genes that are crucial for, or directly
participate in, the metabolism of the metabolite(s) (ATP10
andHAO2, respectively) (Table S2). Asmembers of the type-
IV subfamily of p-type ATPases are aminophospholipid
translocases [38], ATP10 may participate in transport of
arachidonic pathway precursors (phospholipids) that are
metabolized to adrenic acid [39]. Similarly, co-association of
HAO2 and docosahexaenoic acid is appropriate because the
gene is required for metabolism of fatty acids within this
pathway [40]. Direct relationships for the remaining loci
with their associated metabolites were less evident.
Gene expression–metabolite associations
We next investigated the relationship between mRNA
expression and metabolite concentrations. Of the
64 47,009 mRNA–metabolite associations, the 20 stron-
gest associations, ranked by FDR, are shown in Table S3. The
eicosanoid docosatrieneoic acid was the most frequently
observed metabolite among the gene–metabolite pairs, and
was associated with expression of eight genes. The bile acid
metabolites ursodeoxycholyltaurine and ursodeoxycholyl-
glycine were linked to expression of four genes, and
docosapentaneoic acid and glycocholic acid were connected
to single genes (Table S3). An uncharacterized metabolite,
HDHA_1074, was linked to five genes (Table S3). While
there were no statistically significant associations (FDR
< 0.05), in order to prioritize a selection of top hits for
further analysis, we included the top 20 mRNA expression
probes in the Bayesian network methodology. In this case,
without a clear FDR cutoff presenting itself, we chose the top
20 to be similar to the number of top selections identified
from other integrative ‘‘omics’’ analysis.
CpG methylation–metabolite associations
We computed associations of methylation at individual
CpG sites to each of the 64 metabolites, adjusting for age
and the first two PCs. Type I CpG sites and type II CpG
sites were analyzed separately. For type I CpG sites, the
numbers of significant tests (FDR-adjusted p-value <0.05)
for the 64 metabolites were ranged from 0 to 1,463. Fifty-
nine metabolites had at least one significant association.
Table 2. Metabolomic pathways.
Pathway name
Total no. of
metabolites
No. of overlapping
metabolites
Unadjusted
p-value
FDR-adjusted
p-value
Pathway impact
score
Linoleic acid metabolism 15 2 0.61 0.97 0.66
Arachidonic acid metabolism 62 6 0.87 0.97 0.29
Primary bile acid biosynthesis 47 6 0.25 0.72 0.04
Fatty acid metabolism 50 1 0.97 0.97 0.03
Sphingolipid metabolism 25 1 0.27 0.72 0.03
Taurine and hypotaurine
metabolism
20 1 0.15 0.72 0.00
Fatty acid biosynthesis 49 5 0.94 0.97 0.00
Fatty acid elongation in
mitochondria
27 1 0.97 0.97 0.00
Integrative metabolomics of asthma control M. J. McGeachie et al.
230 © 2015 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
The metabolite Taurochenodeoxycholic_acid had the maxi-
mum number of significant metabolite-type-I-CpG asso-
ciation tests. For type II CpG sites, the numbers of
significant tests for the 64 metabolites were ranged from 0
to 3,759. Fifty-nine metabolites had at least one significant
association. The metabolite Taurochenodeoxycholic_acid
had the maximum number of significant metabolite-type-
II-CpG association tests. We kept the top 50 metabolite-
type-I-CpG and metabolite-type-II-CpG association tests,
each of which contained nine unique metabolites. There
were 12 unique metabolites in the two sets of nine
metabolites. For each of the 12 metabolites, we selected the
top two associated CpG sites for further analysis and
inclusion in our Bayesian network methodology. This
resulted in 19 total methylation markers (Table S4). The
markers were annotated to 19 genes, which included
GLCCI1 (which was also associated with taurocholic acid),
an important candidate gene that modulates responses to
steroid treatment in asthmatics [41].
Integrative pathway analysis of metabolite–gene
associations
Docosatrienoic acid had the greatest number of associations
with individual genes, and was also among the top-ranked
associations (Table S3), providing additional evidence that
eicosanoid pathways for linoleic acid and arachidonic acid
(Table 2 and Fig. 4) are important network hubs. We
investigated the biological relevance of the 20 mRNA–
metabolite relationships (shown in Table S3) using IMPaLA
to integrate gene expression and metabolite data.
Twenty-seven metabolites, and 11 of the genes shown in
Table S3, mapped to 17 distinct molecular pathways (the top
10 pathways are listed in Table 3). The most frequently
observed metabolite was arachidonic acid, which appeared
in 12 of the 17 pathways, singly or among related metabolites
(Table 3). In addition, PGE2 and sphingosine-1-phosphate
(S1P) were the second and third most highly represented
metabolites among the pathways (Table 3). Thus, the ORA
Figure 3. Metabolomics pathway analysis. (A) Plot showsmetabolome view of pathway enrichment analysis results in the asthma cohort. In side panels,
metabolic pathways are shown for (B) “Linoleic Acid Metabolism” and (C) “Arachidonic Acid Metabolism”. In B and C, labels within small boxes
correspond to KEGG identiﬁers for metabolites. Box color gradient indicates increasing signiﬁcance values for a given metabolite within the pathway
from least (blue) to the most signiﬁcant (red). Boxplot ﬁgures in B and C represent the median IQR for log-normalized concentrations for the indicated
metabolite, in the cases (teal boxplots) versus controls (red boxplots). In B, corresponding boxplots for linoleic acid (C01595) and g-linoleic acid (C06426)
concentrations are shown. The numerals in C correspond to (1) arachidonic acid (C00219), (2) 5-HETE (C04805), (3) PGE2 (C00584), (4) 12(S)-HPETE
(C05955), (5) 15(S)-HETE (C04742), (6) LTB4 (C02165).
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results were driven by the presence of three metabolites that
either directly represent (or are known to modulate) the
eicosanoids, namely arachidonic acid, PGE2 and S1P.
The largest and best-ranked pathway was ‘‘signal
transduction’’ (Table 3), which contained 18 metabolites
including the docosatrieneoic acid precursor, docosahex-
aenoic acid, as well as other linoleic acid pathway
metabolites. In addition, several pathways contained genes
whose expression was associated with this metabolite,
including CHN1, IFIT3, OASL, and OAS1, which were
present in multiple pathways for immune response, IFN and
cytokine-related signaling (Tables S3 and S4). The pathways
also included the genes GNA12 and PRKCE, of which
PRKCE and GNA12 were well-represented in the top
pathways (Table 3). Finally, through querying PharmGKB35,
we confirmed that OASL and OAS1 also represent
pharmacogenetic loci for interferon-based drugs (data not
shown).
Integrative ORA implicated multiple pathways related to
interferon signaling and sphingolipid signaling that included
Figure 4. Network of molecular interactions for integrative ORA pathway genes. A network was generated for CHN1, PRKCE, GNA12, OASL, OAS1,
ORMDL3, and IFIT3. Nodes (circles) represent genes, and lines between nodes (edges) represent relationships (co-expression, co-localization, shared
protein domains, physical and genetic interactions) between nodes. Node color indicates pathway annotation, and the strength of the evidence in
support of the indicated interaction is shown by edge thickness.
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PRKCE and/orGNA12. As multiple genes were annotated to
the same or redundant pathways, they are likely to have
important, and possibly complementary, roles in these
immune response pathways. UsingCHN1, PRKCE, GNA12,
OASL, OAS1, and IFIT3 as query genes, we generated a
network (GeneMania [36]) of molecular interactions.
Interestingly, this gene network also interacted with an
important asthma susceptibility gene, ORMDL3 [7, 42–44],
and two of its homologs, ORMDL1 and ORMDL2. Genetic
interactions exist between ORMDL3 and GNA12, and
between OASL and ORMDL2, suggesting that these genes
interact within a cellular network (Fig. 4, green lines) [45].
Bayesian network results
In parallel with the ORA-based approach, we implemented a
more statistically driven approach to identify predictors of
asthma control. To this end, we combined the 64metabolites
Table 3. Top 10 pathways for integrative ORA of genes and metabolites.
Pathway name
No. of
overlapping
genes
No. of
overlapping
metabolites
Gene
p-value
Metabolite
p-value
Joint
p-value
Adjusted
joint
p-value
Gene
symbol Metabolites
Signaling by GPCR 2 17 0.31 1.65E20 2.42E19 4.00E17 GNA12,
PRKCE
PGE2, arachidonic acid, cholic acid,
palmitic acid, palmitoleic acid,
all-cis-7,10,13,16-docosatetraenoic
acid, stearic acid, gamma-linolenic
acid, myristic acid, sphingosine
1-phosphate, docosapentaenoic
acid, leukotriene B4,
chenodeoxycholic acid,
eicosatrienoic acid, oleic acid,
eicosapentaenoic acid,
docosahexaenoic acid
Signal transduction 3 18 0.32 1.02E19 1.47E18 9.72E17 GNA12,
PRKCE,
CHN1
Eicosatrienoic acid, arachidonic
acid, cholic acid, palmitic acid,
chenodeoxycholic acid,
all-cis-7,10,13,16-docosatetraenoic
acid, stearic acid, gamma-linolenic
acid, myristic acid, sphingosine
1-phosphate, docosapentaenoic
acid, leukotriene B4, palmitoleic
acid, linoleic acid, PGE2, oleic acid,
eicosapentaenoic acid,
docosahexaenoic acid
Inflammatory
mediator
regulation of TRP
channels—homo
sapiens (human)
1 6 0.10 7.06E08 1.37E07 1.64E06 PRKCE 12(S)-HPETE, 15(S)-HETE,
leukotriene B4, arachidonic acid,
5-HETE, PGE2
GPCR downstream
signaling
2 8 0.26 9.16E08 4.46E07 5.07E06 GNA12,
PRKCE
Cholic acid, palmitic acid,
leukotriene B4,
sphingosine-1-phosphate,
arachidonic acid, oleic acid, PGE2
G-a (q) signaling
events
1 5 0.18 5.00E06 1.36E05 0.000118 PRKCE Palmitic acid, leukotriene B4, oleic
acid, arachidonic acid, PGE2
Gastrin-CREB
signaling pathway
via PKC and MAPK
1 5 0.20 5.00E06 1.49E05 0.000126 PRKCE Palmitic acid, leukotriene B4, oleic
acid, arachidonic acid, PGE2
Fc-g R-mediated phagocytosis—homo sapiens
(human)
1 2 0.091 0.001 0.001 0.005 PRKCE Sphingosine-1-phosphate,
arachidonic acid
S1P5 pathway 1 1 0.008 0.019 0.002 0.007 GNA12 Sphingosine 1-phosphate
S1P4 pathway 1 1 0.015 0.019 0.003 0.011 GNA12 Sphingosine 1-phosphate
S1P2 pathway 1 1 0.027 0.026 0.006 0.022 GNA12 Sphingosine 1-phosphate
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with top association results from the SNP, mRNA expres-
sion, and CpG methylation analysis into a single integrative
‘‘omics’’ dataset, and generated a conditional Gaussian
Bayesian network (CGBN) predictive of asthma control
among the 12 cases and 8 controls in CARE (Fig. 1).
After building a CGBN using bootstrapping and cross-
validation (see Methods), we obtained a consensus network
(Fig. 5), using a low-edge inclusion threshold from the
bootstrap networks (10.4%). This low threshold is indicative
of a variety of different networks generated in bootstrapping
and which is generally a consequence of the low sample-size.
The consensus network was successful at predicting asthma
control in the 20 sample cohort with a CV AUC of 95.31%.
Prediction by a CGBN of a phenotype (blue arrow, Fig. 5)
requires only the nodes within the Markov Neighborhood of
the phenotype (the node’s children, and other parents of
those children). In this case, the predictive ability of the
CGBN is based on twometabolites, Sphingosine 1 Phosphate
(S1P) and monoHETE_0863; and four SNPs, rs9522789 (far
from genes), rs7147228 (intronic to CDKL1), rs7201423 (in
LOC101927131), rs759582 (near CMAS). SNP rs759582 is in
tight LD (r2¼ 0.95) with a SNP, rs56069081, in a DNAseI
hypersensitivity site in a sample of lung tissue tumor
(HaploReg v3, ref). SNP rs9522789 is in tight LD with
rs1578536 (r2¼ 0.87), also in a DNAseI hypersensitivity site,
and one marked with enhancer histones in vascular
endothelial cells (HaploReg). It is possible these SNPs
have regulatory effects, although they are intergenic.
The CGBN network was compared with results fromORA
to determine whether the biologically inferred and statisti-
cally based methods could validate one another. Of the
CBGN predictors, multiple pathways that included S1P as a
major metabolite were identified from the metabolomic and
integrative ORAs. For example, from the metabolomics
ORA of 31 metabolites, ‘‘sphingolipid metabolism’’ had
been identified (Fig. 3A). Furthermore, out of 17 pathways
Figure 5. Consensus Bayesian network. Nodes represent gene expression probe levels, CpG site methylation percents, SNP minor allele distributions,
and metabolite levels. The phenotype, asthma control, is marked with a blue arrow. Nodes with more connections are bigger and redder; gray arrows
between nodes indicate the Bayesian conditional independence of the child node given the parent nodes of the remaining nodes. Thicker
arrows represent stronger statistical dependence.
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identified in the integrative ORA, nine pathways included
S1P (Table 3). These pathways also included the genes
GNA12 and PRKCE, the latter of which also constitutes a
network hub within both CGBN (Fig. 5) and a molecular
interaction network (Fig. 4) that is also predicted to interact
with GNA12.
The S1P pathway is modulated in response to
albuterol: in silico validation using CMAP
To provide insight into potential cellular mechanisms for
asthma control, we searched CMAP [37] to identify lipid
metabolites with gene expression signatures that were
significantly correlated with those resulting from albuterol
(‘‘salbutamol’’) treatment, indicating a commonmechanism
of action.
The CMAP query identified 96 small molecules that were
significantly correlated (p< 0.05) with the gene expression
signature for ‘‘salbutamol,’’ a.k.a. albuterol. Among these
were PGE1 (‘‘alprostadil’’) and PGE2 (‘‘dinoprostol’’),
which were significantly positively correlated with genes
responsive to albuterol (p¼ 2–4 1005) and were also
ranked among the top 10 correlated compounds (Table S6).
As our pathway-based and CGBN analyses both implicated a
role for S1P, which stimulates pro-inflammatory function
via boosting production of PGE2 (the major inflammatory
mediator prostaglandin), we investigated expression of
genes within the albuterol gene signature that were also
upregulated (n¼ 126) or down-regulated (n¼ 169) in
response to treatment with 10mMPGE2. The gene encoding
prostaglandin E synthase (PTGES) was the most highly
upregulated gene, while ADRB2, the molecular target of
albuterol, was down-regulated; as PGE2 negatively regulates
ADRB2, this finding was consistent with previous reports of
these interactions (data not shown). Interestingly, 2 of the 20
candidate genes, ISG20 and OASL, were also present and
highly upregulated (>3.5-fold) in this data set (data not
shown). Importantly, the S1P pathway (Pathway Commons
Pathway ‘‘Sphingosine-1-phosphate (S1P) pathway’’) was
significantly enriched in the PGE2 expression signature
(adjusted p¼ 2.2 1021). Thirteen genes annotated to the
S1P pathway were up-regulated (>1.5-fold), while eight
genes were down-regulated (Table S7).
Discussion
Our study has four key findings. First, our integrative
‘‘omics’’ analysis implicates two pathways—arachidonic
acid metabolism and linoleic acid metabolism—in asthma
control. Second, a Bayesian network of the integrated dataset
predicts uncontrolled asthma with high CV accuracy,
supporting the validity of our integrative approach to
identify important metabolite and gene interactions. Third,
altered sphingolipidmetabolism appears to be an underlying
feature of uncontrolled asthma and cellular response to
albuterol. Finally, our results suggest that albuterol and
PGE2 share common cellular pathways, based on correlated
gene signature expression patterns that include genes
involved in S1P metabolism and/or activity.
The metabolic pathways for the eicosanoids arachidonic
acid and linoleic acid had the highest impact scores. These
two pathways also scored highest for metabolite–mRNA
associations, with the eicosanoid docosatrieneoic acid
represented among the most frequently observed metabo-
lites. Although these results were not significant, the lack of
statistical significance was likely due to our small sample size.
Despite this, these findings still have relevance for asthma, as
arachidonic acid is the precursor for eicosanoid production,
including leukotrienes and prostaglandins, and both 15(S)-
HETE and PGE2 are differentially produced during acute
exacerbations [46]. In addition, linoleic acidmetabolites also
induce airway hyper-responsiveness [47] and variable
linoleic acid exposure influences asthma symptoms [48].
Integrative ORA identified multiple metabolites with
important relationships to genes involved in smooth muscle
contraction, which is an important mechanism of bronchial
hyper-responsiveness and/or airway constriction, and
inflammation. Arachidonic acid can alter inflammatory
gene expression through PRKCE [49, 50] and G-protein
coupled receptor and GTP-ase activity, potentially via
GNA12 and CHN1.
The Bayesian Network based on four SNPs and two
metabolites predicts asthma control with high CV accuracy,
supporting our hypothesis that inclusion of multiple omics
would lead to greater accuracy and while also revealing
important relationships among the metabolites and top
SNPs, genes, and epigenetic marks. Of course, considering
the low sample size in the current work, and the large
network assembled, we cannot rule out overfitting as a cause
of predictive accuracy, although the bootstrapping and
cross-validation methods are designed, along with the
Bayesian priors, to guard against this. We feel that these
findings provide evidence to support the ability of our
methods to identify important metabolite and gene
interactions, and further implicate sphingolipid signaling
as an important metabolomic signature for asthma control.
Furthermore, of these predictors, S1P, was enriched in the
results from integrative andmetabolic ORAs, demonstrating
that both the biologically inferred and statistically based
approaches we applied were complementary, and could
serve to validate one another.
Evidence from both methods implicated sphingolipid
metabolism; in particular, the BN subnetwork of GNA12,
PRKCE and S1P, may represent a potential mechanism for
asthma control.GNA12 encodes guanine nucleotide binding
protein (G-protein) a 12, which couples to the lung and
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lymphoid-tissue specific S1P receptor, S1P(4), in response to
S1P binding [51]. GNA12 also physically interacts with, and
is phosphorylated by, PRKCE [52]. In turn, these genes
interact with a variety of signaling molecules and binding
partners, including genes identified in our analysis such as
CHN1, and the interferon-responsiveOAS and IFIT3 genes,
in order to effect cellular responses. Our finding that altered
sphingolipid metabolism is important in uncontrolled
asthma is supported by several reports describing the role
of sphingolipids in airway inflammation and asthma, and as
therapeutic targets [53, 54]. Furthermore, we explored the
potential interaction of the network genes with ORMDL3, a
negative regulator of sphingolipid biosynthesis with upre-
gulated expression in asthmatics [7]. ORMDL3 also
contributes to airway hyperreactivity through altered
sphingolipid biosynthesis [55]. This study implicates a
role for genes that participate in eicosanoid and sphingolipid
signaling, chiefly GNA12 and PRKCE, that also interact with
ORMDL3 and interferon-responsive OAS and IFI gene
family members, in a molecular interaction network.
As a first step toward functional validation, we
investigated these potential interactions in silico using
CMAP, a publicly available reference database of gene
expression profiles from human cell lines treated with
small molecules that can be mined for shared biological
connections. In this analysis, albuterol gene expression
signatures serve as a cellular proxy for asthma control, and
molecules that demonstrate significantly shared expression
signatures with albuterol are anticipated to share mech-
anisms of action. We determined that the gene expression
signatures for albuterol were highly correlated with PGE2,
and that ISG20 and OASL were both upregulated in
response to treatment with both compounds. Further-
more, 21 additional genes within the S1P metabolic
pathway were differentially expressed.
To our knowledge, few metabolomic studies have been
performed for asthma; most have focused on asthma
diagnosis while two studied asthma severity [14–21]. In
general, these studies had similarly good predictive
accuracy (>80%) in differentiating asthmatics with
good and poor control in our study [14–17]. None of
the prior studies implicated altered sphingolipid metab-
olism. Saude et al. identified five metabolites in the
tricarboxylic acid (TCA) cycle with a higher abundance in
subjects who experienced exacerbations compared to
subjects who did not experience exacerbations [17, 18].
This is consistent with the histamine release that occurs
during mast cell activation in asthma exacerbations [18].
A genomic analysis was also conducted using serum from
asthma patients experiencing serious asthma exacerba-
tions to identify the transcriptional variation during the
process of an exacerbation, which also identified
immune-related genes associated with uncontrolled
asthma [56]. This finding and others are promising,
identifying metabolites related to TCA cycle metabolism,
hypoxic stress, immune reaction and inflammation, all of
which are biologically plausible metabolites for asth-
ma [14, 18].
Notably, our investigation represents the first integra-
tive metabolomics study of asthma, in addition to the first
asthma pharmacometabolomics study conducted to date.
Our approach uses metabolites as intermediate measures
to connect each of the other ‘‘omics’’ data sets. A limited
set of the remaining ‘‘omics’’ was then tested relative to
the clinical outcome. By using either the ORA-based or
CGBN integrated approach, our analysis shows that novel
predictors of asthma control can be reliably identified.
Despite the strengths of our study, a few potential
weaknesses deserve mention. The primary weakness of
this study is the limited sample size. Despite this, both the
statistical and bioinformatics pathway analyses have
consistent results. In addition, there were no clinical,
baseline, or descriptive differences between our cases and
controls, suggesting that the two groups are well matched.
The small sample size and lack of power likely
contributed to our inability to identify statistically
significant associations in some of our single-genomic
modalities, such as the mRNA expression and methyla-
tion analysis. Investigations using larger samples sizes in
the future are warranted. In addition, our study used
blood plasma samples for the omic investigation, and it
may be of future interest to assess these findings in a
respiratory tissue such as lung epithelium or airway
smooth muscle, although previous studies have shown
that asthma exacerbation is detectable from mRNA
expression in blood [56]. Finally, the phenotype assessed
was based on self-reported albuterol use, which may be a
source of bias and represents a limitation of the analysis.
In conclusion, altered sphingolipidmetabolism represents
an underlying feature of both asthma control and cellular
response to albuterol. Lipid mediators play an important
role in airway inflammation and asthma, and sphingolipid
metabolites serve as novel molecular candidates for future
functional validation studies.
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